undamentalytics Newsletter

Wilson Mark Andrew: insider trades

Officer at Nektar Therapeutics. No open-market purchases and 17 sales not made under a pre-set plan, reported from May 20, 2020 to November 25, 2025.

What happened after Wilson Mark Andrew’s sales?

After their sales, the shares moved −40.2% against the index over 12 months on average (a negative figure means selling was the right call); 89% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Wilson Mark Andrew: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 10 −5.9% −12.5% 70% 4 −0.37 0.73 No reliable evidence
Sales, 12 months after the report 9 −40.2% −64.2% 89% 4 −0.17 0.88 No reliable evidence
Sales, 12 months after the trade 9 −38.8% −63.5% 89% 4 −0.14 0.89 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Nektar Therapeutics NKTR Chief Legal Officer017May 20, 2020November 25, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
November 25, 2025November 25, 2025 NKTR Sale $34,196 +2.8%not yetnot yet
August 21, 2025August 19, 2025 NKTR Sale $17,975 +102.5%+157.3%+158.4%
February 21, 2025February 19, 2025 NKTR Sale $11,150 not yetnot yetnot yet
December 26, 2024December 23, 2024 NKTR Sale $44,800 not yetnot yetnot yet
May 20, 2024May 17, 2024 NKTR Sale $10,955 not yetnot yetnot yet
February 17, 2023February 16, 2023 NKTR Sale $24,825 not yetnot yetnot yet
November 18, 2022November 16, 2022 NKTR Sale $31,023 not yetnot yetnot yet
August 17, 2022August 16, 2022 NKTR Sale $15,180 not yetnot yetnot yet
May 17, 2022May 16, 2022 NKTR Sale $12,387 not yetnot yetnot yet
February 18, 2022February 16, 2022 NKTR Sale $40,088 −58.1%−66.1%−65.2%
November 17, 2021November 16, 2021 NKTR Sale $86,382 −3.1%−55.9%−59.1%
August 18, 2021August 16, 2021 NKTR Sale $26,415 −8.5%−62.1%−63.5%
May 19, 2021May 17, 2021 NKTR Sale $35,081 −34.3%−73.5%−76.2%
February 18, 2021February 16, 2021 NKTR Sale $48,610 −34.0%−70.7%−65.0%
November 18, 2020November 16, 2020 NKTR Sale $26,055 +21.7%−64.6%−52.8%
August 19, 2020August 17, 2020 NKTR Sale $30,075 −16.5%−62.1%−63.7%
May 20, 2020May 18, 2020 NKTR Sale $34,418 −31.4%−64.2%−61.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Wilson Mark Andrew traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.